Strut Health in 2026: What It Actually Delivers (and Where It Falls Short)

You've seen Strut Health come up repeatedly in GLP-1 comparison threads — positioned somewhere between the budget telehealth plays and the more clinical longevity clinics. The pitch is clean: async consultations, compounded semaglutide or tirzepatide, no video appointment required. If you're trying to decide whether that model works for you, here's what the numbers and structure actually tell you.

What Strut Health Is, Structurally

Strut operates as an asynchronous telehealth pharmacy platform: you complete an intake questionnaire, a licensed prescriber reviews it, and medications ship directly if approved. There's no synchronous video visit in the standard flow, which is both its efficiency advantage and its clinical limitation. The company has historically focused on dermatology and hair loss alongside weight management, so its GLP-1 offering sits inside a broader, less specialized product portfolio. That shapes what kind of clinical relationship you're walking into.

Pricing and What You're Actually Getting

As of mid-2026, Strut's compounded semaglutide runs approximately $199–$249 per month depending on dose, with tirzepatide priced closer to $299–$349 per month. That puts it in the mid-tier of the compounded GLP-1 market — cheaper than branded Wegovy (list price above $1,300/month without insurance) but not the lowest option available. Platforms including Ivím Health and ReliefSeeker have pushed entry-level compounded semaglutide below $150/month, which matters if you're self-paying for an indefinite maintenance protocol.

The monthly fee at Strut covers the medication and the initial prescriber review but does not include ongoing metabolic lab monitoring. The Endocrine Society's 2023 obesity pharmacotherapy guidelines recommend baseline and periodic monitoring of HbA1c, fasting glucose, and lipid panels for patients on GLP-1 receptor agonists, particularly during titration. If you source labs independently through a direct-to-consumer service such as Labcorp OnDemand or Quest MyQuest, expect to add $80–$150 per panel.

Where the Async Model Creates Real Friction

The no-video-required approach is low-friction for patients who already know their titration schedule and are primarily solving for cost and continuity. For someone carrying over an established GLP-1 protocol, it works.

The friction surfaces during titration problems. Semaglutide is typically initiated at 0.25 mg/week for four weeks before advancing to 0.5 mg/week. The STEP 1 trial (Wilding et al., 2021, n=1,961) documented a 14.9% mean body weight reduction at 68 weeks on the 2.4 mg/week maintenance dose — but reaching that dose safely requires managing GI side effects, which for some patients means slower titration or dose pauses. In an async model, the back-and-forth — "I'm still nauseated at 0.5 mg, do I hold for another two weeks?" — becomes a message thread. Response times at Strut average 24–48 hours, meaning a question that directly affects whether you take your next injection can sit unanswered for two days.

This is a structural limitation of any async-first platform, not a Strut-specific failure. But it's the most consequential difference when evaluating Strut against alternatives. If you want to compare GLP-1 providers that include synchronous options or embedded metabolic coaching, that model difference is decisive.

Compounded Medication Status in 2026

The regulatory picture for compounded semaglutide has shifted. The FDA's updated 503A and 503B pharmacy oversight, following the shortage resolution process that began in late 2024, means compounded semaglutide now occupies a more contested legal position than it did 18 months ago. Some compounders have moved toward tirzepatide as the cleaner ongoing option, given that branded tirzepatide (Zepbound) retains availability gaps in certain dose strengths.

Strut has continued offering compounded semaglutide as of this writing, but its legal exposure is shared with the rest of the compounding telehealth sector. Patients should understand they're not receiving FDA-approved semaglutide — they're receiving a compounded equivalent, which carries different quality assurance and regulatory guarantees. That's not disqualifying, but it's not the same product as Ozempic or Wegovy.

How It Stacks Against Comparable Platforms

On the best online GLP-1 programs comparison, Strut typically ranks well on price-to-access ratio but scores lower on clinical depth — specifically on integrated lab monitoring, synchronous prescriber access, and structured titration protocols. Hims/Hers includes a dedicated clinical team and structured check-in cadence within its GLP-1 program. Eden Health bundles primary care with its weight management track. Several newer longevity-adjacent platforms, including Fountain Life and Lifeforce, build explicit lab review cycles into their protocols. Each offers more clinical scaffolding than Strut at comparable or only modestly higher price points.

Where Strut outperforms most of those: the pharmacy-direct model produces faster medication delivery, and the intake interface is genuinely simple. For maintaining an established protocol with minimal administrative overhead, that combination has real value.

The Practical Verdict

Strut Health works best as a maintenance platform for patients who already understand their titration schedule, have a separate primary care relationship handling their labs, and are optimizing for cost and convenience over clinical guidance. At $199–$249/month for compounded semaglutide, it's not the cheapest option, but it's operationally competent for that narrow use case.

If you're starting GLP-1 therapy for the first time, or still in the dose-finding phase, the async model leaves gaps that a more integrated program fills. The browse online programs directory lets you filter by consultation type, monitoring inclusion, and medication category — a faster way to identify whether Strut's structure matches your clinical situation or whether Hims/Hers, Eden, or a longevity-focused alternative is the better fit.

Strut is closer to a pharmacy than a clinical partner. If you need the latter, look elsewhere.

---

Peptide Clinic Finder is a comparison platform. The author may receive compensation if you sign up through links on our partner pages.

---